Insights on the Hemoglobinopathies Global Market to 2031 - Increasing Prevalence of Hemoglobinopathies in Under-Developed and Developing Countries is Driving Growth - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--Nov 21, 2022--

The "Hemoglobinopathies Market By Type, By Therapy, By Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

According to this report the hemoglobinopathies market was valued at $4.2 billion in 2021, and is estimated to reach $7 billion by 2031, growing at a CAGR of 5.2% from 2022 to 2031.

Hemoglobinopathy is a collective term used for the blood disorder that primarily affects the red blood cells (RBCs). The abnormal production or structural change in the hemoglobin molecule causes hemoglobinopathies. Majorly, hemoglobinopathies are divided into two groups, namely abnormal structural hemoglobin variant and thalassemia.

The abnormal structural hemoglobin variants are caused by mutations in the hemoglobin gene structure and thalassemia is occurred by abnormal or underproduction of hemoglobin molecules. Many hemoglobinopathies currently have some approved drugs in the market and some drugs are in development stages.

The increasing prevalence of sickle cell disease (SCD) and thalassemia is expected to drive the market growth. The key driver for the growth of the global hemoglobinopathies market is increasing prevalence of hemoglobinopathies in under-developed and developing countries. In addition, the lack of awareness and low diagnosis rate are some major factors increasing the prevalence of the hemoglobinopathies.

Moreover, the lack of treatment alternatives, unavailability of treatments and low diagnosis rate are the factors restraining the growth of the global hemoglobinopathies market during the forecast period. The hemoglobinopathies market is projected to grow with the arrival of treatments for beta thalassemia and sickle cell diseases.

Treatments based on transfer of genetically corrected stem cells, in which the lentiviral vectors transfer beta globin chain, and the transcription is regulated by the beta globin locus. For instance, there are various factors limiting growth of the market, such as insufficient stem-cell quantity and quality, gene expression complexity, and high cost of the treatment.

Key Benefits

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hemoglobinopathies market analysis from 2021 to 2031 to identify the prevailing hemoglobinopathies market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the hemoglobinopathies market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global hemoglobinopathies market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

• Thalassemia
• Sickle Cell Disease
• Others

By Therapy

• Monoclonal Antibody Medication
• ACE inhibitors
• Hydroxyurea
• Others

By Distribution Channel

• Hospital Pharmacy
• Online Providers
• Drug Stores and Retail Pharmacy

By Region

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• Japan
• China
• Australia
• India
• South Korea
• Rest of Asia-Pacific
• LAMEA
• Brazil
• Saudi Arabia
• South Africa
• Rest of LAMEA

Key Market Players

• Abbott Laboratories
• Alnylam Pharmaceuticals, Inc.
• Biogen idc
• Bluebird, Inc.
• Bristol Myers Squibb
• Danaher Corporation
• Emmaus Life Sciences, Inc.
• Global Blood Therapeutics, Inc.
• Merck & Co. Inc.
• Novartis AG
• Pfizer
• Prolong Pharmaceuticals
• Sangamo Therapeutics, Inc.
• Sanofi
• Cancer Therapeutics CRC Pty Ltd
• Gamida-Cell Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/pec7dw

View source version on businesswire.com:https://www.businesswire.com/news/home/20221121005352/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2022.